![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/09\/20260917_Longeveron_Therapeutic_Indications-768x432.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Longeveron<\/p>\n Event Type<\/strong><\/p>\n Clinical Trial Readout<\/p>\n Modality<\/strong><\/p>\n Cell Therapy (Allogeneic Mesenchymal Stromal Cells)<\/p>\n Asset<\/strong><\/p>\n Laromestrocel<\/p>\n Target<\/strong><\/p>\n Paracrine Pro-Vascular \/ Anti-Inflammatory Signaling (Non-Specific)<\/p>\n Disease Area<\/strong><\/p>\n Hypoplastic Left Heart Syndrome<\/p>\n Laromestrocel did not improve the primary Month-12 right-ventricular ejection-fraction endpoint in the randomized, 40-infant ELPIS II study of hypoplastic left heart syndrome. The least-squares mean difference was -0.7 percentage points versus surgery alone, with a 95% confidence interval spanning -7.3 to 5.9 and a P value of 0.8336. No new safety signal emerged, and exploratory event trends favored treatment numerically, but those trends were not statistically significant and cannot rescue the failed primary analysis.<\/p>\n Longeveron released topline data on September 16, 2026. Infants in the trial received intramyocardial allogeneic bone-marrow-derived mesenchymal stromal cells during Stage II surgical palliation, or surgery alone. A hierarchical exploratory composite of mortality and hospitalization was not statistically significant, and hospitalization burden was similar between arms. In the as-treated population, there were no deaths among 17 treated children versus one death among 21 controls, and major adverse cardiac events numbered 12 versus 19.<\/p>\n Treatment-emergent adverse events occurred in 94.1% of treated infants versus 100% of controls, and serious adverse events occurred in 64.7% versus 71.4%; none was considered treatment related. Longeveron said it would pursue strategic options and cash conservation following the miss. The FDA had previously indicated that ventricular ejection fraction alone would not be sufficient to establish efficacy, which limits the endpoint’s standalone regulatory value even had it been met.<\/p>\n One interpretation is that a single intramyocardial cell dose simply does not produce a measurable improvement in ventricular function at one year in this population. The point estimate sits near zero with a wide confidence interval, consistent with an absence of demonstrated benefit. A competing interpretation is that survival or morbidity, rather than ejection fraction, could be the more biologically meaningful readout in a fragile congenital population. That is plausible, but the prespecified exploratory composite of mortality and hospitalization also failed to reach significance, and the favorable numerical trends in death and major adverse cardiac events rest on small, sparse event counts that are hypothesis-generating at best, not confirmatory.<\/p>\n The trial’s small size (40 infants) limits statistical power to detect a true effect on hard outcomes even if one exists, and the as-treated comparisons are subject to the usual caveats of non-randomized subgroup analysis. Any future program would need a larger sample, a regulator-aligned clinical endpoint, and either partnership or fresh financing; the current dataset does not establish efficacy under any of the endpoints tested.<\/p>\n Longeveron develops laromestrocel, an allogeneic mesenchymal stromal-cell product derived from young adult bone marrow. Proposed mechanisms include paracrine pro-vascular, anti-inflammatory, and tissue-repair signaling rather than durable cell engraftment or replacement. Hypoplastic left heart syndrome is a severe congenital defect requiring staged surgical palliation, in which the right ventricle is left to support the systemic circulation; morbidity and transplant risk are high, making hard clinical outcomes important but difficult to power in small rare-pediatric-disease trials.<\/p>\n ELPIS II is a negative clinical readout, notwithstanding an acceptable safety profile and favorable but statistically unsupported numerical event counts. The primary endpoint failed decisively and the prespecified exploratory composite did not reach significance. A credible path forward would require a regulator-aligned hard-outcome endpoint, a larger and adequately powered trial, and new financing or a development partner; the current data do not establish efficacy for laromestrocel in hypoplastic left heart syndrome.<\/p>\n Signal importance is high given the randomized, rare-pediatric cell-therapy design and the strategic inflection it creates for Longeveron, but the direction is negative since neither the primary endpoint nor the exploratory composite was met; confidence in the underlying facts is high because the company disclosed patient counts, effect estimates, confidence intervals, P values, and safety data, while confidence in interpretation is moderate given the trial’s small size and immature event follow-up.<\/p>\n","protected":false},"excerpt":{"rendered":" Laromestrocel did not improve the primary Month-12 right-ventricular ejection-fraction endpoint in the randomized, 40-infant ELPIS II study of hypoplastic left heart syndrome. The least-squares mean difference was -0.7 percentage points versus surgery alone, with…<\/p>\n","protected":false},"author":1,"featured_media":3286,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[254,808,807],"class_list":["post-3266","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-cell-therapy","tag-hypoplastic-left-heart-syndrome","tag-longeveron"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3266","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3266"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3266\/revisions"}],"predecessor-version":[{"id":3298,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3266\/revisions\/3298"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3286"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3266"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3266"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Deep Analysis<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n